{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:30:32Z","timestamp":1791509432680,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00403-020-02108-8","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T19:02:25Z","timestamp":1596222145000},"page":"357-365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Oral mycophenolate mofetil as a stabilizing treatment for progressive non-segmental vitiligo: results from a prospective, randomized, investigator-blinded pilot study"],"prefix":"10.1007","volume":"313","author":[{"given":"Anuradha","family":"Bishnoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshavamurthy","family":"Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu Sendhil","family":"Kumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-0815","authenticated-orcid":false,"given":"Davinder","family":"Parsad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"2108_CR1","doi-asserted-by":"crossref","unstructured":"Bishnoi A, Parsad D. Clinical and Molecular Aspects of Vitiligo Treatments. Int J Mol Sci. 2018;19.","DOI":"10.3390\/ijms19051509"},{"key":"2108_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1365-4362.1993.tb02754.x","volume":"32","author":"JS Pasricha","year":"1993","unstructured":"Pasricha JS, Khaitan BK (1993) Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 32:753\u2013757","journal-title":"Int J Dermatol"},{"key":"2108_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2310\/7750.2013.12053","volume":"17","author":"AJ Kanwar","year":"2013","unstructured":"Kanwar AJ, Mahajan R, Parsad D (2013) Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg 17:259\u2013268","journal-title":"J Cutan Med Surg"},{"key":"2108_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1529-8019.2010.01328.x","volume":"23","author":"D Parsad","year":"2010","unstructured":"Parsad D, Kanwar A (2010) Oral minocycline in the treatment of vitiligo\u2013a preliminary study. Dermatol Ther 23:305\u2013307","journal-title":"Dermatol Ther"},{"key":"2108_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/0378-6323.125479","volume":"80","author":"A Singh","year":"2014","unstructured":"Singh A, Kanwar AJ, Parsad D et al (2014) Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J Dermatol Venereol Leprol 80:29\u201335","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2108_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000433424","volume":"231","author":"H Singh","year":"2015","unstructured":"Singh H, Kumaran MS, Bains A et al (2015) A Randomized Comparative Study of Oral Corticosteroid Minipulse and Low-Dose Oral Methotrexate in the Treatment of Unstable Vitiligo. Dermatology 231:286\u2013290","journal-title":"Dermatology"},{"key":"2108_CR7","doi-asserted-by":"crossref","unstructured":"Patra S, Khaitan BK, Sharma VK, et al. A randomized comparative study of the effect of betamethasone oral mini-pulse therapy versus oral azathioprine in progressive non-segmental vitiligo. J Am Acad Dermatol. 2019.","DOI":"10.1016\/j.jaad.2019.03.025"},{"key":"2108_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5826\/dpc.0702a06","volume":"7","author":"F Handjani","year":"2017","unstructured":"Handjani F, Aghaei S, Moezzi I et al (2017) Topical mycophenolate mofetil in the treatment of vitiligo: a pilot study. Dermatol Pract Concept 7:31\u201333","journal-title":"Dermatol Pract Concept"},{"key":"2108_CR9","first-page":"407","volume":"135","author":"MD Njoo","year":"1999","unstructured":"Njoo MD, Das PK, Bos JD et al (1999) Association of the Kobner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol 135:407\u2013413","journal-title":"Arch Dermatol"},{"key":"2108_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1477-7525-1-58","volume":"1","author":"D Parsad","year":"2003","unstructured":"Parsad D, Dogra S, Kanwar AJ (2003) Quality of life in patients with vitiligo. Health Qual Life Outcomes 1:58","journal-title":"Health Qual Life Outcomes"},{"key":"2108_CR11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/bjd.13093","volume":"171","author":"V Gupta","year":"2014","unstructured":"Gupta V, Sreenivas V, Mehta M et al (2014) Measurement properties of the Vitiligo Impact Scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument. Br J Dermatol 171:1084\u20131090","journal-title":"Br J Dermatol"},{"key":"2108_CR12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","volume":"153","author":"JM Bae","year":"2017","unstructured":"Bae JM, Jung HM, Hong BY et al (2017) Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol 153:666\u2013674","journal-title":"JAMA Dermatol"},{"key":"2108_CR13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/j.1468-3083.2007.02283.x","volume":"21","author":"A Bhatnagar","year":"2007","unstructured":"Bhatnagar A, Kanwar AJ, Parsad D et al (2007) Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: an open prospective comparative study. J Eur Acad Dermatol Venereol 21:1381\u20131385","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 1","key":"2108_CR14","doi-asserted-by":"publisher","first-page":"s2","DOI":"10.1191\/0961203305LU2109OA","volume":"14","author":"AC Allison","year":"2005","unstructured":"Allison AC (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14(Suppl 1):s2\u20138","journal-title":"Lupus"},{"key":"2108_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jid.2018.10.032","volume":"139","author":"JM Richmond","year":"2019","unstructured":"Richmond JM, Strassner JP, Rashighi M et al (2019) Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo. J Invest Dermatol 139:769\u2013778","journal-title":"J Invest Dermatol"},{"key":"2108_CR16","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/S0041-1345(01)01965-0","volume":"33","author":"K Izeradjene","year":"2001","unstructured":"Izeradjene K, Quemeneur L, Michallet MC et al (2001) Mycophenolate mofetil interferes with interferon gamma production in T-cell activation models. Transplant Proc 33:2110\u20132111","journal-title":"Transplant Proc"},{"key":"2108_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4103\/0019-5154.53185","volume":"54","author":"I Majid","year":"2009","unstructured":"Majid I, Masood Q, Hassan I et al (2009) Childhood vitiligo: response to methylprednisolone oral minipulse therapy and topical fluticasone combination. Indian J Dermatol 54:124\u2013127","journal-title":"Indian J Dermatol"},{"key":"2108_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/j.1365-2133.2012.11056.x","volume":"167","author":"V Eleftheriadou","year":"2012","unstructured":"Eleftheriadou V, Thomas KS, Whitton ME et al (2012) Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials. Br J Dermatol 167:804\u2013814","journal-title":"Br J Dermatol"},{"key":"2108_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000251114","volume":"153","author":"S Imamura","year":"1976","unstructured":"Imamura S, Tagami H (1976) Treatment of vitiligo with oral corticosteroids. Dermatologica 153:179\u2013185","journal-title":"Dermatologica"},{"key":"2108_CR20","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1067\/mjd.2001.113475","volume":"44","author":"S Radakovic-Fijan","year":"2001","unstructured":"Radakovic-Fijan S, Furnsinn-Friedl AM, Honigsmann H et al (2001) Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 44:814\u2013817","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-020-02108-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-020-02108-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-020-02108-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T23:56:54Z","timestamp":1627689414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-020-02108-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["2108"],"URL":"https:\/\/doi.org\/10.1007\/s00403-020-02108-8","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"5 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding source"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}